{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CERT",
  "name": "Certara, Inc.",
  "url": "https://frontierpicks.com/dossiers/CERT/",
  "json_url": "https://frontierpicks.com/dossiers/CERT.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Guidance held rather than got cut again: the 2026-08-04 Q2 print reaffirmed FY26 revenue $367-382M and adj EPS $0.31-0.36 despite a revenue miss, and the $6.87 premarket gap round-tripped to an $8.43 close on 08-21. The leg is self-help — ~5% RIF for ~$13M run-rate savings, $98.21M of stock retired, software bookings +9% — with no dated catalyst until the ~2026-11-03 Q3 print.",
  "invalidation_trigger": "A daily close below $7.20 surrenders the entire post-print recovery off the 2026-08-04 gap; secondarily, FY26 revenue guided under $367M or adjusted EPS under $0.31 at the Q3 report (~2026-11-03, est.) would end the self-help read.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "ai-enterprise-software",
    "precision-biotech-therapeutics",
    "cyclical-industrials"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "No permanent CFO: Faiz Mohammed has been interim since 2026-07-15, after John E. Gallagher III resigned effective 2026-07-14.",
    "YoY comparisons are distorted by the May 2026 divestiture of the medical and regulatory writing unit to Veristat; results are presented on a continuing-operations mix.",
    "Segment reporting is in transition — the company reorganized into two units, MID3 and ACE, in May 2026, so prior software/services splits are not clean comparables.",
    "Shareholder-investigation notices have circulated since roughly 2026-06-21 following the 2026-05-11 guidance revision; no filed complaint is confirmed in public sources here.",
    "The company corrected a statement made on the 2026-08-04 call about the divested unit's 2025 adjusted EBITDA, putting it near $23M excluding corporate expense."
  ],
  "body_markdown": "## Current Thesis\nOne correction to the frame carried since early August, because it changes what the tape was reacting to: the FY2026 range was **reaffirmed** at the 2026-08-04 Q2 print, not revised down a second time. The release carries revenue $367–382M (0–4% growth), adjusted EBITDA margin 29–31%, adjusted diluted EPS $0.31–0.36 and 155–157M fully diluted shares. So the gap that opened to $6.87 in the premarket on 2026-08-04 — roughly 16% under the $8.18 prior close\n\nThe leg an investor is buying is self-help arithmetic on a flat top line. A reduction in force of roughly 5% of the global workforce carries approximately $13M of expected run-rate savings, including stranded costs from the divested medical and regulatory writing unit. The $100M repurchase program was completed — and the board authorized a further $50M with no expiration. Software revenue reached $48.8M (+4%) with software bookings $50.7M (+9%). The 2026-07-07 NVIDIA agentic-framework partnership over the Simcyp engine sits on top as unpaid-for optionality.\n\nThe narrative is **maturing**, dated 2026-08-07 → 2026-08-21. The recovery held for two more weeks and added about 2.8%, but there has been no fresh headline since the 08-04 print, RSI(14) sits at 55.2 rather than extended, and the next dated company event that resolves anything is the Q3 report around 2026-11-03. Attention arrived on 08-04; it has not expanded since.\n\n## Bull Case\n- **The guide held under pressure (2026-08-04):** revenue $367–382M, adjusted EBITDA margin 29–31%, adjusted diluted EPS $0.31–0.36 reaffirmed alongside a revenue miss. A reaffirmation delivered on a miss is a harder datapoint than one delivered on a beat.\n- **Quantified cost takeout, first carried in Q3:** approximately 5% of the global workforce cut, weighted to overhead, for approximately $13M of run-rate savings (Q2 release, 2026-08-04). Adjusted EBITDA was $26.2M in Q2, down 3% YoY — the cost programme is the bridge to the 29–31% margin guide.\n- **Float is shrinking with cash, not diluting:** 12,377,833 shares repurchased for $98.21M completed the prior authorization, and $50M more was approved on 2026-08-04. Fully diluted share guidance of 155–157M for FY26 compares with 152.54M shares outstanding reported on 2026-08-07.\n- **Software is the growing half:** software revenue $48.8M (+4% YoY) and software bookings $50.7M (+9% YoY) in Q2 2026, the mix the May 2026 reorganization into MID3 and ACE was built around.\n- well under the 2026-08-21 close of $8.43.\n- **The AI link is infrastructure, not a banner:** the 2026-07-07 NVIDIA partnership places agentic frameworks over the Simcyp PBPK engine and regulatory datasets used by the FDA and other agencies.\n\n## Bear Case\n- **The shrinking half is nearly half the business:** services revenue $44.5M, down 3% YoY, with services bookings $47.6M, down 6% YoY. Total bookings of $98.3M grew 1%.\n- **Reported profitability is negative:** net loss from continuing operations of $6.1M in Q2 2026 against $1.5M of net income in Q2 2025; diluted EPS $(0.04). Simply Wall St's Q2 summary cites a total-company net loss of $55.27M once discontinued operations are included.\n- **The sell-side marks the stock at or below spot:** Barclays raised its target to $7.50 from $6.50 on 2026-08-05 at Equal Weight; Simply Wall St reported an August 2026 consensus target of $8.71 against the 2026-08-21 close of $8.43. There is little published upside cushion above the market.\n- **Finance leadership is still temporary:** Faiz Mohammed has served as interim CFO since 2026-07-15, after John E. Gallagher III resigned effective 2026-07-14, and signed the Q2 10-Q certification in that capacity on 2026-08-04. Commercial leadership also turned over — Julien Perrier became Chief Commercial Officer effective 2026-08-01 following the departure of President and CCO Leif Pedersen, with Eric Jahn named CIO.\n- **A disclosure had to be corrected:** the company amended a statement made on the 2026-08-04 call about the divested regulatory and medical writing unit's 2025 adjusted EBITDA, putting it at approximately $23M excluding corporate expense, per TipRanks' 2026-08 report of the correction. Management said reported results and the 2026 outlook were unaffected.\n- **The move is a repair, not a breakout:** the 2026-08-21 close of $8.43 sits 38.0% below the $13.6 52-week high, with a three-month price change of +60.9% off a washed-out low.\n\n## Setup & Price Structure\n- Reference close 2026-08-21: $8.43. RSI(14) 55.2 — mid-range, neither extended nor oversold. Distance below the 52-week high of $13.6 is 38.0%; three-month price change of +60.9%.\n- The structure to watch is the post-print shelf: closes of $8.13 on 2026-08-06 and $8.20 on 2026-08-07, built directly off the 2026-08-04 gap that printed $6.87 premarket and recovered to roughly $7.20 intraday. Two subsequent weeks added about 2.8% without giving that shelf back.\n- Positioning observables, stated as observables: the consensus target of $8.71 sits roughly 3% above the last close and the most recent single-firm target on the wire ($7.50, Barclays, 2026-08-05) sits below it; the company is a buyer of its own shares under a $50M authorization rather than an issuer into strength; there is no earnings date inside 30 days; retail-sentiment coverage has not clustered around the name since the 07-07 NVIDIA headline, and the two Benzinga items on that date are the most recent name-specific wire coverage in the 30-day window.\n- What is absent matters: no confirmed insider purchase or sale in the public record reviewed here, and no new sell-side initiation since the print.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-22 → 2026-09-21: no company-confirmed investor event.** The Q2 Form 10-Q was filed 2026-08-04, concurrent with the release, and the Q2 13F deadline of 2026-08-14 has passed. The 30-day window is empty of scheduled guidance events.\n- **~2026-09-21 (est.):** Certara's own events listing shows a company-hosted event at the Cambridge Innovation Center, Cambridge MA. Scientific/user programming, not a guidance or capital-markets event — it resolves nothing in the numbers.\n- **~2026-11-03 (est.):** Q3 2026 results — the first quarter carrying the ~$13M of run-rate savings and the first clean ex-divestiture comparison.\n- **2026-11-14:** Q3 13F deadline, which shows whether BlackRock's 11.60% stake held through the print.\n\n## Elapsed catalysts\n\n- **Undated, any session:** an 8-K naming a permanent CFO. The search has been open since 2026-06-11. *(passed 76d ago)*\n\n## What Would Change Our Mind\nThe structure that carries the read is the $8.13–$8.20 shelf built on 2026-08-06 and 2026-08-07 and held through 2026-08-21; the level that says the repair failed is the print-day recovery low. A daily close below $7.20 surrenders the entire post-print recovery off the 2026-08-04 gap and puts the $6.87 premarket print back in play.\n\nOn fundamentals, three observables would break the self-help read independently of price: FY26 revenue guided below $367M or adjusted EPS below $0.31 at the Q3 report (~2026-11-03, est.), which would make this the third downward revision of 2026; adjusted EBITDA margin printing under the 29% floor of the reaffirmed guide despite a completed reduction in force, which would mean the ~$13M was absorbed rather than banked; or software bookings growth decelerating below the +9% posted in Q2 2026, which removes the one line that is compounding.\n\nA fourth, softer condition: the narrative flipping to saturated without a bookings inflection — mainstream coverage arriving on the AI-partnership angle while services bookings stay negative — would mean the bid is headline-sourced. Conversely, a permanent CFO named before the Q3 print and repurchases visible under the new $50M authorization in the Q3 10-Q would extend the current read rather than end it.\n\n## Correlation Notes\n- Trades with the small-cap life-science tools and CRO complex and with biotech funding proxies; software is 52% of Q2 revenue ($48.8M of $93.3M), so small-cap software multiple compression transmits as well.\n- The 2026-07-07 NVIDIA partnership means AI-in-drug-discovery headlines can bid the shares independent of bookings — a channel that opened in July and has not been retested.\n- Market capitalization was $1.25B on 152.54M shares at the 2026-08-07 close. At that scale, buyback demand under the $50M authorization and index/13F rebalance flow are material to the tape in a way they are not for larger comparables.\n- Guidance revisions in this group cluster: pharma R&D budget commentary from larger tools names is a leading read on the services line that has now declined for consecutive quarters.",
  "first_seen": "2026-07-14",
  "last_analyzed": "2026-08-22T10:39:44+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}